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Abstract: Honey bee venom has been established to have significant effect in immunotherapy. In
the present study, (Z)-11-eicosenol-a major constituent of bee venom, along with its derivations
methyl cis-11-eicosenoate and cis-11-eicosenoic acid, were synthesised to investigate their immune
stimulatory effect and possible use as vaccine adjuvants. Stimuli that prime and activate the immune
system have exerted profound effects on immune cells, particularly macrophages; however, the
effectiveness of bee venom constituents as immune stimulants has not yet been established. Here,
the abilities of these compounds to act as pro-inflammatory stimuli were assessed, either alone
or in combination with lipopolysaccharide (LPS), by examining the secretion of tumour necrosis
factor-α (TNF-α) and the cytokines interleukin-1β (IL-1β), IL-6 and IL-10 by THP-1 macrophages.
The compounds clearly increased the levels of IL-1β and decreased IL-10, whereas a decrease in IL-6
levels suggested a complex mechanism of action. A more in-depth profile of macrophage behaviour
was therefore obtained by comprehensive untargeted metabolic profiling of the cells using liquid
chromatography mass spectrometry (LC-MS) to confirm the ability of the eicosanoids to trigger the
immune system. The level of 358 polar and 315 non-polar metabolites were changed significantly
(p < 0.05) by all treatments. The LPS-stimulated production of most of the inflammatory metabolite
biomarkers in glycolysis, the tricarboxylic acid (TCA) cycle, the pentose phosphate pathway, purine,
pyrimidine and fatty acids metabolism were significantly enhanced by all three compounds, and
particularly by methyl cis-11-eicosenoate and cis-11-eicosenoic acid. These findings support the
proposed actions of (Z)-11-eicosenol, methyl cis-11-eicosenoate and cis-11-eicosenoic acid as immune
system stimulators.
Keywords: (Z)-11-eicosenol; methyl cis-11-eicosenoate; cis-11-eicosenoic acid; pro- and
anti-inflammatory cytokines; LPS stimulation; THP-1 cells; macrophages; adjuvant vaccine
1. Introduction
Adjuvants, in the context of vaccines, are described as substances capable of enhancing and
modulating antigen-specific immune responses to improve vaccine efficacy [1]. The immune stimulating
effects of adjuvants was first established with the addition of aluminium potassium sulphate or
aluminium salts to human vaccines [2,3]. Today, a better understanding of immune responses has
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increased the availability and variety of vaccine adjuvants to include virosomes, MF59 and AS04 [3].
Adjuvants are now in widespread use, but their development has been empirical, without a clear
understanding of their molecular and cellular mechanisms of action. However, several studies have
suggested that adjuvants act by enhancing T and B cell responses, by stimulating innate immunity and
by increasing the magnitude of the adaptive responses to the vaccine [4–6]. Adjuvants also stimulate
a strong and comprehensive immune response to antigen by mimicking natural defensive trigger
molecules, such as endogenous immune-active substances (e.g., chemokines and cytokines) or other
natural compounds (e.g., vitamin E and saponins) [3].
A crucial need exists for the development and investigation of new vaccine adjuvant compounds
that have the ability to induce immune responses. However, the molecular and cellular mechanisms
that regulate the activity of the majority of human-licensed adjuvants are still only partially
characterised. The adjuvant derivatives of bacterial components, such as lipopolysaccharide (LPS),
cytidine–phosphate–guanosine (CpG) oligonucleotides and monophosphoryl lipid A (MPL), are
probably the most characterised at present [7]. MPL works as an agonist of Toll-like receptor (TLR4),
which is expressed on antigen presenting cells (APCs), such as dendritic cells (DCs) and macrophages,
and promotes cytokine expression, antigen presentation and migration of the APCs to the T-cell
area [8,9]. These compounds act as microbial sensors called pathogen-associated molecular patterns
(PAMPs), and they activate pattern recognition receptors (PRR) and subsequently TLR [10].
LPS is the most widely studied of the TLR4 ligands, and its adjuvant derivatives (which are less
toxic) have been the basis of virtually all clinical trials of adjuvant TLR4 agonists [11]. The interactions
of LPS derivatives with TLR4 are restricted mainly to their lipid A portion, which are composed of
polyacylated diglucosamine lipids [12]. A combination of specific adjuvants with TLR agonists has
been proposed to optimise vaccines [13]. Therefore, evaluation of the LPS enhancement of cytokine
productions and a metabolic interpretation of LPS immune-modulatory effects would be a promising
strategy for investigating proposed new adjuvants.
Honey bee (Apis mellifera) venom is a very complex mixture of substances, including organics,
peptides and enzymes. These ingredients contribute a variety of biological activities towards the
overall toxic shock [14], and have attracted attention as possible leads for drug discovery. Some
components have been applied to the treatment of inflammation and cancer, for example, [15,16], but
their use as vaccine adjuvants is still under investigation. Melittin, a major lytic peptide found in bee
venom, has been proposed as a vaccine adjuvant due to its confirmed ability to enhance TNF-α, IL-1β
and IL-6 cytokine production within the THP-1 monocyte-derived macrophage cell line [17,18].
An organic compound of interest in honey bee venom is (Z)-11-eicosen-1-ol. This is a major
component of the alarm pheromone mixture co-secreted with the venom [19]. Insect pheromones are
typically volatile organics that are released to warn of danger [20]. (Z)-11-eicosen-1-ol prolongs the
effectiveness of isopentyl acetate, another key component of the alarm pheromone secretion, thereby
increasing the speed of the aggressive response [14,19]. A similar compound, (Z)-9-eicosen-1-ol, was
detected in A. mellifera venom, resembling the compound described by Pickett et al. and differing only
with respect to the double bond position [18]. It was found to enhance the release of pro-inflammatory
cytokines, other than IL-6 [18].
Immune metabolism is a rapidly growing area of research. Recently, several studies have shown
the importance of metabolites, such as succinate and itaconate, in the modulation of the innate immune
response of macrophages [21,22]. The exposure of macrophages to various immune stimuli, including
pathogenic antigens and cytokines, initiates several signaling cascades by interactions with receptors
(i.e., cytokine receptors or PRR) [23]. This intracellular and extracellular signaling is expected to
elicit major changes in metabolites to promote the required alteration of the cell phenotype and
changes in anabolic and catabolic pathways [23]. Immune cells use different metabolic pathways to
provide adequate energy generation and cell survival during cell growth and proliferation. These
metabolic pathways, which include fatty acid synthesis, rely on products from other pathways, such as
glycolysis and the tricarboxylic acid (TCA) cycle, to provide key synthetic precursors [24]. For this
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reason, metabolomics analysis of immune cells can provide a more complete understanding of the
physiological state of an organism and of the alterations occurring in the metabolome, as metabolites
are often considered the end stage of biological processes.
A growing number of findings highlight the crucial role of metabolic reprogramming in
macrophage activation. Immune cells utilise five metabolic pathways: glycolysis, the TCA cycle, the
pentose phosphate pathway (PPP), fatty acid synthesis and amino acid metabolism [24]. The present
study investigated the metabolic responses of phorbol 12-myristate 13-acetate (PMA)-differentiated
THP-1 cells treated with three different forms of synthetic honey bee venom eicosenoid compounds:
(Z)-11-eicosenol, methyl cis-11-eicosenoate and cis-11-eicosenoic acid. The overall goal was to determine
how these compounds might trigger an immune response and further used as vaccine adjuvants.
Comprehensive metabolic profiling and assessments of pro- and anti-inflammatory cytokines (TNF-α,
IL-1β, IL-6 and IL-10) were also conducted following exposure of LPS-stimulated THP-1 macrophage
cells with these compounds. The observation of a synergistic effect of the investigated compounds
with LPS in enhancement of immune stimulatory activation and cytokine production suggested the
potential use of honey bee venom components as immune-modulatory agents and as vaccine adjuvants,
which support their use as pro- rather than anti-inflammatory agents.
2. Materials and Methods
2.1. Sample Preparation
Methyl cis-11-eicosenoate (CAS 2390-09-2) and cis-11-eicosenoic acid (CAS 5561-99-9) were
purchased from Sigma-Aldrich and used directly.
Cis (Z)-11-eicosenol (CAS 62442-62-0) was obtained by selective reduction of methyl
cis-11-eicosenoate with lithium aluminium hydride. Briefly, dry diethyl ether was added to the
hydride and stirred in an ice bath for 30 min. The ester was added dropwise, stirred for 30 min, then
refluxed gently for 60 min. The reaction mixture was worked up by quenching with wet ether and
washing with potassium sodium tartrate solution and water. The extracted organic layer was dried
over sodium sulphate, filtered and excess solvent evaporated with an air stream to obtain the product.
Confirmation of the reduction was obtained via IR and the full structure of the intended product was
confirmed by NMR, including by 1D 1H and 13C-{1H} NMR spectra and 2D [1H, 13C]-HSQC and 2D
[1H, 1H] DQFCOSY and TOCSY NMR spectra Data and their assignments were confirmed directly
with that of the natural product as previously assigned [18].
1H NMR (1D, 600 MHz, DMSO-d6): δH 0.84–0.86 (t, J = 13 Hz, 3H, C1), 1.24–1.30 (m, 26H,
C2/C3/C4/C5/C6/C7/C12/C13/C14/C15/C16/C17/C18), 1.35–1.40 (m, 2H, C19) 1.96–1.99 (q, J = 19 Hz, 4H,
C8/C11), 3.35–3.38 (m, 2H, C20), 4.30–4.31 (m, 1H, OH), 5.29–5.34 (sept, 2H, C9/10).
13C-{1H} NMR (1D, 150 MHz, DMSO- d6): δ 13.90 (C1), 22.07 (C2), 25.50 (C18), 26.53 (C8/C11),
28.56 (C5), 28.67 (C6), 28.81 (C7), 28.85 (C12), 28.95 (C14), 29.00 (C15), 29.07 (C16), 29.08 (C17), 31.28
(C3), 32.54 (C19), 60.70 (C20), 129.61 (C9/C10).
2.2. Cell Culture and Differentiation
THP-1 cells (American Type Culture Collection, ATCC®, Manassas, VA, USA) were cultured to a
seeding density of 1 × 105 cells/mL in Roswell Park Memorial Institute (RPMI) medium 1640 (Thermo
Fisher Scientific, Loughborough, UK) with addition of L-glutamine (2 mmol/L, Life Tech, Paisley, UK),
foetal calf serum (FCS, 10% v/v, Life Tech) and penicillin/streptomycin (100 IU/100 µg/mL, Life Tech).
Sub-cultures were prepared every 2 to 4 days in fresh media and incubated at 37 ◦C and 100% humidity
in 5% CO2 prior to differentiation by addition of phorbol 12-myristate 13-acetate (PMA, 60 ng/mL final
concentration, Sigma-Aldrich, Dorset, UK). The cells were then incubated for 48 h, after which the
PMA-containing media were replaced with fresh media and the cells rested for an additional 24 h prior
to examination by light microscopy.
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2.3. Cell Viability Assay
THP-1 cells were cultured in 96-well plates at a seeding density of 1 × 105 cells/mL. The cells
were incubated for 24 h at 37 ◦C and 100% humidity in 5% CO2 prior to treatment with eicosenoid
compounds at various concentrations (1.2 to 150 µg/mL) followed by a further 24 h incubation. Controls
included cells alone (no treatment), medium alone (background) and dimethyl sulphoxide (1.5% v/v
DMSO, positive) were added. The plates were then incubated for an additional 24 h following
addition of resazurin salt solution (0.1 mg/mL, 10% v/v final concentration) before examining the
fluorescence at λEx = 560 nm and λEm = 590 nm (SpectraMax M5, Molecular Devices, Sunnyvale, CA,
USA). A background correction was performed and the call viability for each treatment concentration
was determined with respect to the mean viability of the negative control (n = 3). Mean inhibitory
concentration (IC50) values and dose–response curves were obtained using GraphPad Prism for
Windows v 5.00 (GraphPad Software, San Diego, CA, USA).
2.4. Cytokine Production
The differentiated cells were incubated for a further 24 h in the presence and absence of LPS
(0.5 µg/mL, Sigma-Aldrich) with the final eicosenoid concentrations presented in Table 1. The prepared
medium was obtained and frozen until needed for the enzyme-linked immunosorbent assay (ELISA)
(n = 3).
Table 1. Sample groups, IC50 concentrations and final chosen concentrations of synthetic bee venom
compounds tested in phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 cells.
Synthetic Compounds
IC50 (µg/mL) Selected Final Concentration (µg/mL)
Group ID Chemical Name
11E-OH (Z)-11-eicosenol 19.88 9.0
11E-ester methyl cis-11-eicosenoate >150 150
11E-acid cis-11-eicosenoic acid 90.98 40.0
IC: inhibitory concentration.
2.5. Enzyme-Linked Immunosorbent Assay (ELISA)
The production of inflammatory cytokines TNF-α, IL-1β, IL-6 and IL-10 were quantified using
ELISA Ready-Set-Go kits (Thermo Fisher Scientific, Bremen, Germany) in accordance with the supplier’s
protocol. Sulphuric acid solution (2N) was added to stop the reaction prior to reading the absorbance
at 560 nm (SpectraMax M5, Molecular Devices) and subtracting the absorbance at 570 nm.
2.6. Metabolite Extraction
THP-1 cells differentiated with PMA were cultured in 6-well plates at a seeding density of 4.5 ×
105 cells/mL (n = 6) for 48 h, after which the medium was removed by aspiration and replaced prior to
incubation with LPS (0.5 µg/mL) either alone or together with (Z)-11-eicosenol (9 µg/mL), eicosenoate
(150 µg/mL) and eicosenoic acid (40 µg/mL) for another 24 h. Extraction of the metabolites was carried
out as described previously [17]. Seven different analytical standard solutions were prepared by adding
each metabolite standard (10 µg/mL final concentration) containing glycine-13C2 [25]. Combined
quality control (QC) samples were prepared by pipetting 20 µL from each individual sample, mixing
and transferring to a high-performance liquid chromatography (HPLC) vial.
2.7. LC-MS Conditions
LC-MS was carried out using an Exactive Orbitrap (Thermo Fisher Scientific, Bremen, Germany);
the conditions used were as described in our previous paper [17].
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2.8. Data Extraction and Statistical Analysis
Data extraction was performed using the MZMatch software (SourceForge, La Jolla, CA, USA) and
the metabolite peaks were filtered, compared and characterised using the Microsoft Excel IDEOM [26]
as described in our previous paper [17]. The metabolite data were also subjected to multivariate
analysis by fitting PCA-X and OPLS-DA using the SIMCA-P software v.14.0 (Umetrics, Umea, Sweden).
Univariate comparisons were performed using Microsoft Excel and paired t-tests between treated and
control cells and differences were considered significant at p < 0.05. Using ELISA, standard calibration
curves were plotted by fitting the average optical density (OD) values of TNF-α, IL-1β, IL-6 and IL-10
to 4-parameter logistic (4-PL) regression curves. Each standard concentration assayed in duplicate
(n = 2), as shown in Figures S1–S12.
3. Results
3.1. Cytotoxicity of Eicosenoid Compounds against PMA-Differentiated THP-1 Cells
The potential cytotoxicity of (Z)-11-eicosenol (11E-OH), eicosenoate (11E-ester) and eicosenoic
acid (11E-acid) (Figure 1) on PMA-differentiated THP-1 cells was evaluated to select an appropriate
final concentration for further tests. Clear dose-dependent toxicity to THP-1 cells was observed for
11E-OH and its 11E-acid form. The lowest IC50 value at 19.88 µg/mL was observed for 11E-OH,
whereas this value was 90.98 µg/mL for 11E-acid (Figure 2A–C). By contrast, the 11E-ester form was
nontoxic to THP-1 cells, with an IC50 value greater than 150 µg/mL. ELISAs were also conducted
to assess the cytokine levels in THP-1 derived-macrophage cells upon treatment with these three
compounds. As shown in Table 1, the final concentrations for cytokine assessments were chosen as
those that were below the IC50 values and resulted in >90% of the cells remaining viable. There was no
difference in effect between the solvent control DMSO alone (1.5% final concentration) and negative
control media on cell viability.
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Figure 2. Cytotoxic effects of eicosenoid compounds at varying doses on phorbol 12-myristate 
13-acetate (PMA)-differentiated THP-1 cells. (A) (Z)-11-eicosenol (11E-OH) compound was cytotoxic 
to PMA-treated cells. (B) Eicosenoate (11E-ester) compound was non-cytotoxic to PMA-treated cells. 
(C) Eicosenoic acid (11E-acid) compound was cytotoxic to PMA-treated cells. Each data point 
represents the mean ± SD (n = 3). 
3.2. Effect of Eicosenoid Compounds on Pro-Inflammatory TNF-α Cytokine Production 
Using ELISA, the effects of the eicosenoid compounds on the production of TNF-α cytokine are 
shown in Figure 3 and Table S1. The levels of secreted TNF-α by PMA-differentiated THP-1 cells 
were slightly or negligibly affected by all three forms of eicosanoid when combined with LPS. The 
increase was only statistically significant (p < 0.05) with 11E-acid when compared with LPS alone. 
(Z)-11-eicosenol compounds on their own significantly enhanced the production of TNF-α when 
compared with untreated cells. 
Figure 2. Cytotoxic effects of eicosenoid compounds at varying doses on phorbol 12-myristate
13-acetate (PMA)-differentiated THP-1 cells. (A) (Z)-11-eicosenol (11E-OH) compound was cytotoxic to
PMA-treated cells. (B) Eicosenoate (11E-ester) compound was non-cytotoxic to PMA-treated cells. (C)
Eicosenoic acid (11E-acid) compound was cytotoxic to PMA-treated cells. Each data point represents
the mean ± SD (n = 3).
3.2. Effect of Eicosenoid Compounds on Pro-Inflammatory TNF-α Cytokine Production
Using ELISA, the effects of the eicosenoid compounds on the production of TNF-α cytokine are
shown in Figure 3 and Table S1. The levels f secreted TNF-α by PMA-differentiated THP-1 cells
were slightly or negligibly ffected by all three orms of eicosanoid when combined with LPS. The
incr ase was only statist cally significant (p < 0.05) with 11E-acid when compared with LPS alone.
(Z)-11-eicosenol compounds on their own significantly enhanced the production of TNF-α whe
compared with untreated cell .
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release of IL-1β was greatly enhanced (ratio > 1.0) by approximately 84% and was statistically 
significant when compared with LPS alone. (Z)-11-eicosenol (~50%) enhanced the production of this 
cytokine upon stimulation with LPS, although the increase was not significant when compared with 
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Figure 3. Effect of eicosenoid compounds on the production of TNF-α by PMA-differentiated THP-1
cells in the absence and presence of LPS (0.5 µg/mL). The TNF-α levels were significantly increased by
11E-acid when compared with LPS alone (n = 3). Ctr: Untreated control; LPS: Lipopolysaccharide;
(11E-OH): (Z)-11-eicosenol; (11E-ester): Eicosenoate; (11E-acid): Eicosenoic acid; *: Significant (p < 0.05);
**: Significant (p < 0.01).
3.3. Effect of Eicosenoid Compounds on Pro-Inflammatory IL-1β Cytokine Production
Compared to TNF-α, the enhancement in the production of IL-1β by (Z)-11-eicosenol, eicosenoate
and eicosenoic acid in LPS co-stimul ted THP-1 cells was much more pronounced. The release of
IL-1β w s greatly enhanced (ratio > 1.0) by approximately 84% and was statistically significant when
compared with LPS alone. (Z)-11-ei osenol (~50%) enhanced the production of this cytokine upon
stimulation with LPS, althoug the increase was not significant when compared with LPS alone
(Figure 4 and Table S2). The level of IL-1β was e hanced by (Z)-11-eicosenol and eicosenoic acid
alone, in the absence of LPS, wh n compared with the untreated control; however, the effects were ot
statistically s gnificant.
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eicosenoate (11E-ester) in the presence of LPS (Figure 5). Unstimulated macrophage-like THP-1 cells 
did not produce any IL-6. The same was true for cells stimulated with eicosenoids alone (Table S3). 
Effect of eicosenoid compounds on IL-6 production in
PMA-differentiated THP-1 cells
C
tr
11
E-
O
H
11
E-
es
te
r
11
E-
ac
id
11
E-
O
H
11
E-
es
te
r
11
E-
ac
id
0
20
40
60
80
100
120
140
Sample+LPSSample only
LPS
* **
**
IL
-6
 (p
g/
m
l)
 
Figure 5. Effect of eicosenoid compounds on the production of IL-6 by phorbol 12-myristate 
13-acetate (PMA)-differentiated THP-1 cells in the absence and presence of LPS (0.5 µg/mL). The IL-6 
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Figure 4. Effect of eicosenoid compounds on the production of IL-1β by phorbol 12-myristate 13-acetate
(PMA)-differentiated THP-1 cells in the absence and presence of LPS (0.5 µg/mL). The IL-1β levels were
significantly enhanced in 11E-ester and 11E-acid combination treatments when compared with LPS
alone (n = 3). Ctr: Untreated control; LPS: Lipopolysaccharide; (11E-OH): (Z)-11-eicosenol; (11E-ester):
Eicosenoate; (11E-acid): Eicosenoic acid; *: Significant (p < 0.05); **: Significant (p < 0.01).
3.4. Effect of Eicosenoid Compounds on Pro-Inflammatory IL-6 Cytokine Production
The levels of IL-6 cytokine were evaluated to confirm the previously reported decrease in response
to eicosenoid compounds [18]. A decrease in IL-6 levels in THP-1 derived macrophage cells was also
observ d in the present study in response to all three forms of synthetical prepar eicosenoids.
The lev ls of this cytokine were significantly decreased (p < 0.05) when compared with LPS alone.
Surpri ingly, no detectabl amou t of IL-6 was produc d by the cells treated with eicosenoate (11E-ester)
in th presence of LPS (Figure 5). Unstimulated macrophage-lik THP-1 cells did not pr duce any IL-6.
The same was true for cells stimula ed with eicosenoids alone (Table S3).
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Figure 5. Effect of eicosenoid compounds on the production of IL-6 by phorbol 12-myristate 
13-acetate (PMA)-differentiated THP-1 cells in the absence and presence of LPS (0.5 µg/mL). The IL-6 
levels were significantly decreased in all three combination treatments when compared with positive 
Figure 5. Effect of eicosenoid compounds on the production of IL-6 by phorbol 12-myristate 13-acetate
(PMA)-differentiated THP-1 cells in the absence and presence of LPS (0.5 µg/mL). The IL-6 levels
were significantly decreased in all three combination treatments when compared with positive control
LPS (n = 3). Ctr: Untreated control; LPS: Lipopolysaccharide; (11E-OH): (Z)-11-eicosenol; (11E-e ter):
Eicosenoate; (11E-acid): Eicosenoic acid; *: Signific nt (p < 0.05); **: Significant (p < 0.01).
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3.5. Effect of Eicosenoid Compounds on Anti-Inflammatory Il-10 Cytokine Production
A decrease in the levels of the anti-inflammatory IL-10 cytokine would support the use of
the eicosenoid compounds as immune response stimulators. Combination treatments with LPS
significantly decreased the level of this cytokine in PMA-differentiated THP-1 cells when compared
with LPS alone. The extent of the reductions in the release of IL-10 were about 30%, 80% and 50% in
response to (Z)-11-eicosenol, eicosenoate and eicosenoic acid treatments, respectively, when compared
to treatment with LPS alone (Figure 6 and Table S4).
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Untargeted metabolic profiling of PMA-differentiated THP-1 cells was performed using LC-MS 
analysis. Samples were prepared by incubation of the macrophage cells with LPS and one of the 
three forms of the eicosenoids and compared to control untreated cells (C). Multivariate and 
univariate statistical analysis were used to visualise and examine the metabolite effects on the 
following treatment combinations: T1 (9 µg/mL (Z)-11-eicosenol + 0.5 µg/mL LPS), T2 (150 µg/mL 
eicosenoate + 0.5 µg/mL LPS) and T3 (40 µg/mL eicosenoic acid + 0.5 µg/mL LPS). The effect of LPS 
alone was also evaluated to confirm the previous findings [17] and to investigate new pathways that 
might be involved in immune stimulation by eicosenoids. LPS synergism was clearly evident from 
the cytokine assessment, particularly with IL-1β and IL-10. Further metabolic profiling of these 
combination treatments would aid in determining how they inhibit or stimulate the immune 
response. 
As shown in Figure 7A, principle component analysis (PCA) showed an absence of outliers. In 
addition, pooled quality control samples (QC, P1–6) produced a single tight cluster in the centre of 
the dataset, confirming the stability, precision and validity of the instrumental analytical method. 
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Figure 6. Effect of eicosenoid compounds on the production of IL-10 by phorbol 12-myristate 13-acetate
(PMA)-differ n iated THP-1 cells in the ab ence and presence of LPS (0.5 µg/mL). The IL-10 levels
were significantly ecreased in all three combi ation treatm nts when compared with positive control
LPS (n = 3). Ctr: Untreated control; LPS: Lipopolysaccharide; (11E-OH): (Z)-11-eicosenol; (11E-ester):
Eicosenoate; (11E-acid): Eicosenoic acid; **: Significant (p < 0.01); ***: Significant (p < 0.001).
3.6. Effect of Eicosenoid Compounds on Polar THP-1 Cell Metabolites
Untargeted metabolic profiling of PMA-differentiated THP-1 cells was performed using LC-MS
analysis. Samples were prepare by incubation of the macrophage cells with LPS and one of the three
forms of the eicosenoids and compared to control untreated cells (C). Multivariate and univariate
statistical analysis were used to visualise and examine the metabolite effects on the following treatment
combinations: T1 (9 µg/mL (Z)-11-eicosenol + 0.5 µg/mL LPS), T2 (150 µg/mL eicosenoate + 0.5 µg/mL
LPS) and T3 (40 µg/mL eicosenoic acid + 0.5 µg/mL LPS). The effect of LPS alone was also evaluated
to confirm the previous findings [17] and to investigate new pathways that might be involved in
immune stimulation by eicosenoids. LPS synergism was clearly evident from the cytokine assessment,
particularly with IL-1β and IL-10. Further metabolic profiling of these combination treatments would
aid in determining how they inhibit or stimulate the immune response.
As shown in Figure 7A, principle component analysis (PCA) showed an absence of outliers. In
addition, pooled quality control samples (QC, P1–6) produced a single tight cluster in the centre of
the dataset, confirming the stability, precision and validity of the instrumental analytical method.
Orthogonal partial least squares discriminant analysis (OPLS-DA), a supervised model for sample
classification, showed a clear separation of each combination treatment, indicating unique metabolite
profiling (Figure 7B). The OPLS-DA model parameters and validation of the plot suggest a strong
model, with the p value associated with the cross-validation (CV)-ANOVA = 1.96 × 10−21, indicating
that the model was valid.
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Figure 7. (A) Principle component analysis (PCA-X) vs. (B) Orthogonal Partial Least Squares
Discriminant Analysis (OPLS-DA) score plots of THP-1 cells. The figures show a clear separation
between control, pooled and treatment groups based on 358 polar metabolites separated on a ZIC-pHILIC
column (n = 6). PCA score plot (A) gives the goodness of fit (R2X) = 0.807, and the goodness of
prediction (Q2) = 0.641. OPLS-DA score plot (B) gives R2X = 0.829, R2Y = 0.962, Q2 = 0.874. (C: Control;
LPS: Lipopolysaccharides; T1(1–6): (11E-OH) (Z)-11-eicosenol + LPS; T2(1–6): (11E-ester) Eicosenoate +
LPS; T3(1–6): (11E-acid) Eicosenoic acid + LPS; p = pooled samples).
Pooled quality control samples were injected at intervals (n = 6) during the course of the run
and used for further filtra i n of the dataset based on relative sta dard deviations (RSD). Metabolites
with RSD values >30% within pooled samples were exclude . The univariate analysis shown
in Table 2 reveals a large number of m tabolic changes resulting from applic ion of e cosenoid
treatm nts. Greater effects were observed with the 11E-ester and 11E-acid forms when combined
with LPS and compa ed to untr ated control cells. Increases in abundance were detected for a large
number of metabolites, including arginine and proline, Krebs cycle (TCA cycle) compounds and purine
metabolites, which are all critically involved in inflammatory processes and immune response of
the cells.
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Table 2. Significantly changed polar metabolites in THP-1 cells treated with lipopolysaccharide (LPS), alone or in combination with one of three synthetic forms of
honey bee eicosenoids (0.5 µg/mL LPS; 9 µg/mL 11E-OH; 150 µg/mL 11E-ester; 40 µg/mL 11E-acid). Data are compared with those from untreated control cells.
Mass Rt Putative Metabolite
LPS/C 11E-OH + LPS/C 11E-Ester + LPS/C 11E-Acid + LPS/C
Ratio p Value Ratio p Value Ratio p Value Ratio p Value
Arginine and Proline Metabolism
129.090 15.79 4-Guanidinobutanal 1.523 0.030 1.580 0.008 0.880 ns 1.539 0.010
111.032 20.00 Pyrrole-2-carboxylate 1.200 0.012 1.384 <0.001 1.068 ns 1.260 0.003
189.064 14.09 N-Acetyl-l-glutamate * 0.547 0.007 0.599 0.001 1.139 ns 0.757 0.031
132.054 14.39 N-Carbamoylsarcosine 1.100 ns 1.051 ns 1.395 0.003 1.367 0.011
240.122 16.51 Homocarnosine 1.382 0.049 0.900 ns 1.593 <0.001 1.866 <0.001
211.036 15.28 Phosphocreatine * 0.944 ns 0.970 ns 1.723 0.001 1.285 0.024
113.059 9.94 Creatinine 1.625 ns 0.939 ns 2.104 <0.001 2.199 <0.001
130.122 26.73 Agmatine 1.509 0.021 1.041 ns 2.149 <0.001 1.884 <0.001
129.043 10.08 Oxoproline * 1.732 0.013 0.850 ns 2.331 <0.001 2.525 <0.001
175.096 16.21 L-Citrulline * 1.554 0.011 0.923 ns 2.379 <0.001 2.180 <0.001
246.133 18.71 N2-(d-1-Carboxyethyl)-l-arginine 2.225 0.008 1.233 ns 3.317 <0.001 3.245 <0.001
290.122 16.97 N-(l-Arginino)succinate 0.794 ns 1.022 ns 1.153 ns 1.596 0.015
115.063 13.07 l-Proline * 1.102 ns 0.897 ns 0.995 ns 1.208 0.036
174.112 26.73 l-Arginine * 1.593 0.022 1.089 ns 2.172 <0.001 2.160 <0.001
132.090 26.73 l-Ornithine * 1.834 0.003 1.223 ns 2.665 <0.001 2.501 <0.001
Glycolysis/TCA cycle
260.030 16.93 d-Glucose 1-phosphate * 1.231 ns 1.450 <0.001 0.833 ns 1.508 0.001
180.063 15.08 d-Glucose * 3.076 <0.001 1.901 <0.001 3.638 <0.001 3.309 <0.001
339.996 18.13 d-Fructose 1,6-bisphosphate * 1.789 <0.001 1.930 <0.001 2.217 <0.001 1.734 <0.001
260.030 16.10 d-Fructose 6-phosphate * 1.580 <0.001 1.716 <0.001 1.515 <0.001 1.653 <0.001
169.998 16.16 d-Glyceraldehyde 3-phosphate * 0.600 <0.001 0.441 <0.001 0.519 <0.001 0.404 <0.001
185.993 16.75 3-Phospho-d-glycerate 0.775 ns 1.849 ns 0.886 ns 0.934 ns
169.998 15.33 Glycerone phosphate 1.244 ns 2.368 0.014 1.804 <0.001 1.293 0.023
177.943 15.96 Pyrophosphate 0.832 0.002 0.946 ns 1.040 ns 1.015 ns
97.977 15.96 Orthophosphate 0.768 0.003 0.912 ns 1.031 ns 1.036 ns
192.027 18.13 Citrate * 1.594 <0.001 1.187 0.021 1.939 <0.001 1.904 <0.001
134.022 15.88 (S)-Malate * 1.116 ns 0.943 ns 0.869 0.002 1.124 ns
174.016 18.13 cis-Aconitate * 1.265 ns 0.984 ns 1.662 0.001 1.633 0.001
192.027 19.36 Isocitrate * 1.388 ns 1.493 ns 2.417 0.002 1.788 0.014
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Table 2. Cont.
Mass Rt Putative Metabolite
LPS/C 11E-OH + LPS/C 11E-Ester + LPS/C 11E-Acid + LPS/C
Ratio p Value Ratio p Value Ratio p Value Ratio p Value
116.011 15.02 Fumarate * 1.186 ns 0.831 ns 1.445 0.002 1.826 <0.001
118.027 14.98 Succinate * 1.557 0.002 1.170 ns 1.346 0.005 1.819 0.001
131.070 14.97 Creatine * 1.437 0.001 1.061 ns 3.014 <0.001 1.365 0.002
809.126 12.49 Acetyl-CoA 0.730 0.006 0.907 ns 1.001 ns 0.995 ns
665.125 13.44 NADH * 0.553 <0.001 0.642 <0.001 1.330 ns 0.752 0.008
663.109 14.39 NAD+ * 0.490 <0.001 0.499 <0.001 0.683 <0.001 0.548 <0.001
506.995 16.67 ATP * 0.689 0.002 0.769 0.001 0.584 <0.001 0.724 0.001
427.030 15.30 ADP * 0.598 <0.001 0.671 <0.001 0.638 <0.001 0.762 <0.001
443.024 18.01 GDP * 0.772 0.011 0.978 ns 1.004 ns 0.931 ns
522.990 19.36 GTP * 0.975 ns 1.385 0.003 1.297 0.002 1.051 ns
Oxidative Stress/Pentose Phosphate Pathway
370.007 18.36 d-Sedoheptulose 1,7-bisphosphate 1.475 0.002 1.817 <0.001 1.565 <0.001 1.513 <0.001
232.035 15.75 d-Ribitol 5-phosphate * 0.683 0.007 0.744 ns 0.563 0.002 0.862 0.027
276.025 17.73 6-Phospho-d-gluconate * 1.606 0.006 1.480 0.004 0.568 0.001 0.921 ns
196.058 13.26 d-Gluconic acid * 0.886 ns 0.800 <0.001 0.795 0.002 0.925 ns
150.053 13.64 d-Ribose 1.307 0.017 0.899 ns 1.286 0.018 1.289 0.011
290.040 16.33 d-Sedoheptulose 7-phosphate 1.481 0.001 2.016 <0.001 1.654 <0.001 1.884 <0.001
230.019 15.35 d-Ribulose 5-phosphate 1.566 ns 4.634 0.030 1.410 0.010 1.438 0.007
230.019 15.75 d-Ribose 5-phosphate * 1.525 <0.001 1.516 <0.001 1.796 <0.001 1.230 <0.001
745.091 17.14 NADPH * 0.733 0.002 0.331 <0.001 00.00 n/a 0.347 0.004
743.076 16.87 NADP+ * 0.722 0.024 1.983 <0.001 1.879 <0.001 2.419 0.001
152.068 13.11 Xylitol * 1.423 0.001 1.063 ns 0.907 ns 1.189 0.049
196.058 13.89 d-Mannonate 2.006 ns 0.860 ns 2.406 <0.001 2.454 <0.001
166.048 13.43 d-Xylonate 1.673 0.019 0.929 ns 3.156 <0.001 2.964 <0.001
150.053 13.64 d-Ribose 1.307 0.017 0.899 ns 1.286 0.018 1.289 0.011
307.084 14.37 Glutathione 0.691 <0.001 0.774 <0.001 0.683 <0.001 0.738 <0.001
612.152 17.52 Glutathione disulfide * 1.113 ns 1.679 0.003 3.605 <0.001 3.221 <0.001
Purine Metabolism
363.058 19.36 Guanosine 3’-phosphate 0.909 ns 1.551 0.005 1.406 0.001 1.043 ns
168.028 12.41 Urate * 1.487 ns 0.738 ns 1.778 0.003 2.285 0.001
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Table 2. Cont.
Mass Rt Putative Metabolite
LPS/C 11E-OH + LPS/C 11E-Ester + LPS/C 11E-Acid + LPS/C
Ratio p Value Ratio p Value Ratio p Value Ratio p Value
268.081 11.11 Inosine * 1.804 0.004 5.853 <0.001 12.553 <0.001 9.126 <0.001
283.092 12.83 Guanosine * 1.454 ns 4.991 <0.001 16.908 <0.001 4.976 <0.001
136.038 10.39 Hypoxanthine * 33.258 <0.001 31.216 <0.001 56.447 <0.001 67.586 <0.001
284.075 12.01 Xanthosine * 1.564 0.004 1.306 0.020 1.651 0.003 1.825 0.001
152.033 11.31 Xanthine * 1.907 0.005 1.171 ns 2.376 <0.001 2.492 <0.001
363.058 16.78 GMP * 1.016 ns 1.100 ns 0.809 ns 1.201 0.006
363.058 19.36 Guanosine 3’-phosphate 0.909 ns 1.551 0.005 1.406 0.001 1.043 ns
283.092 12.83 Guanosine * 1.454 ns 4.991 <0.001 16.908 <0.001 4.976 <0.001
347.063 13.89 AMP * 0.656 <0.001 0.660 0.001 0.326 <0.001 0.680 <0.001
Pyrimidine Metabolism
483.968 17.92 UTP * 0.355 <0.001 0.440 <0.001 0.393 <0.001 0.417 <0.001
308.041 13.81 dUMP 0.357 <0.001 0.394 <0.001 0.548 <0.001 0.394 <0.001
482.984 18.48 CTP * 0.473 <0.001 0.596 <0.001 0.688 <0.001 0.492 <0.001
403.018 17.14 CDP * 0.363 <0.001 0.440 <0.001 0.822 ns 0.541 <0.001
323.052 15.35 CMP * 0.763 0.001 0.882 0.040 1.148 ns 0.999 ns
128.058 10.57 5,6-Dihydrothymine 1.664 ns 0.698 0.006 1.395 0.007 2.075 0.033
126.043 15.31 Thymine 1.439 0.031 1.125 ns 1.995 <0.001 1.893 0.001
125.059 10.93 5-Methylcytosine 1.826 ns 1.021 ns 2.013 <0.001 2.139 0.002
244.069 12.15 Pseudouridine 1.780 0.007 1.058 ns 2.266 <0.001 2.134 <0.001
243.085 12.15 Cytidine * 3.051 0.009 1.812 ns 4.662 <0.001 4.849 <0.001
176.043 16.65 N-Carbamoyl-l-aspartate 0.576 <0.001 0.446 <0.001 0.295 <0.001 0.351 <0.001
324.036 15.18 UMP * 0.417 <0.001 0.412 <0.001 0.475 <0.001 0.482 <0.001
404.002 16.59 UDP * 0.218 <0.001 0.347 <0.001 0.413 <0.001 0.350 <0.001
536.044 16.19 UDP-d-xylose 0.593 <0.001 0.699 0.001 1.017 ns 0.745 0.002
580.034 18.96 UDP-glucuronate 0.615 <0.001 0.736 <0.001 0.701 <0.001 0.664 <0.001
566.055 16.31 UDP-glucose * 0.539 <0.001 0.662 <0.001 0.628 <0.001 0.620 <0.001
Tryptophan Metabolism
175.063 10.37 Indole-3-acetate 1.537 <0.001 1.545 <0.001 0.417 <0.001 1.527 <0.001
236.079 10.37 l-Formylkynurenine 1.507 0.002 1.431 <0.001 0.418 <0.001 1.453 <0.001
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Table 2. Cont.
Mass Rt Putative Metabolite
LPS/C 11E-OH + LPS/C 11E-Ester + LPS/C 11E-Acid + LPS/C
Ratio p Value Ratio p Value Ratio p Value Ratio p Value
191.058 10.37 5-Hydroxyindoleacetate * 1.512 <0.001 1.506 <0.001 0.523 <0.001 1.547 <0.001
208.085 11.15 l-Kynurenine * 1.483 ns 1.114 ns 1.565 0.003 2.087 <0.001
220.085 9.99 5-Hydroxy-l-tryptophan isomer 8.354 <0.001 7.721 <0.001 1.655 0.007 8.798 <0.001
205.074 7.56 Indolelactate 2.315 0.009 1.399 ns 2.267 <0.001 3.333 <0.001
117.058 11.92 Indole * 1.413 0.011 1.216 ns 3.554 <0.001 2.257 <0.001
204.090 11.91 l-Tryptophan * 1.311 ns 1.050 ns 3.194 <0.001 2.019 0.003
Miscellaneous
146.069 15.31 l-Glutamine * 1.445 0.001 1.105 ns 1.965 <0.001 1.889 <0.001
147.053 14.71 d-Glutamate * 1.035 ns 0.777 0.002 1.259 0.002 1.355 0.003
301.056 14.93 N-Acetyl-d-glucosamine 6-phosphate * 0.785 0.006 0.755 <0.001 0.642 <0.001 0.878 ns
103.100 20.65 Choline * 1.277 ns 1.336 0.002 1.268 0.005 1.944 <0.001
141.019 15.91 Ethanolamine phosphate * 0.869 ns 0.987 ns 0.555 <0.001 0.797 0.016
105.043 16.02 l-Serine * 1.646 0.004 1.228 0.030 1.835 <0.001 1.927 <0.001
119.058 14.68 l-Threonine 2.719 <0.001 1.618 0.001 3.190 <0.001 2.821 <0.001
155.070 15.16 l-Histidine * 2.450 <0.001 1.285 0.018 3.175 <0.001 2.737 <0.001
146.106 25.28 l-Lysine * 1.520 0.001 1.254 0.017 1.862 <0.001 1.734 <0.001
384.122 13.99 S-Adenosyl-l-homocysteine * 1.163 ns 1.047 ns 1.580 0.001 1.545 0.002
203.116 11.29 O-Acetylcarnitine * 0.702 0.001 0.688 <0.001 0.644 <0.001 0.689 0.001
175.048 14.53 N-Acetyl-l-aspartate * 0.758 0.003 0.628 <0.001 0.797 0.003 0.970 ns
133.038 15.04 l-Aspartate * 1.136 ns 0.888 ns 1.306 0.003 1.618 <0.001
89.048 14.97 l-Alanine * 0.671 0.001 0.731 0.004 1.041 ns 0.720 0.001
226.106 16.03 Carnosine * 1.088 ns 1.080 ns 1.203 0.016 1.201 0.012
132.054 15.48 l-Asparagine * 1.211 ns 0.798 ns 1.310 0.001 1.416 0.001
149.051 11.79 l-Methionine * 1.358 ns 0.910 ns 1.822 <0.001 1.869 <0.001
222.067 17.33 Cystathionine * 0.714 ns 0.833 ns 0.508 <0.001 0.811 ns
181.074 13.24 l-Tyrosine * 1.360 ns 0.989 ns 1.930 <0.001 1.840 0.001
131.095 11.11 l-Leucine * 1.383 0.007 0.962 ns 1.836 <0.001 1.949 <0.001
131.094 11.51 l-Isoleucine * 1.424 ns 0.915 ns 1.838 <0.001 1.852 <0.001
117.079 12.77 l-Valine * 1.739 0.006 1.045 ns 1.901 <0.001 1.876 <0.001
Rt: Retention time (min); LPS: Lipopolysaccharides; *: Matches the analytical standard retention time; ns: Non-significant; n/a: Not applicable.
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3.7. Effect of Eicosenoid Compounds on Lipophilic Metabolites
In order to gain a comprehensive overview, further analysis was also carried out on the non-polar
lipophilic metabolites in the cells using a reversed phase (RP) column. As shown in Figure 8A, PCA
was employed for the 314 lipophilic compounds and shows the absence of the outliers. In addition,
pooled quality control samples (QC, P1–6) clustered together which indicates the stability, precision and
validity of the instrumental analytical method. OPLS-DA shows a clear separation of each combination
treatment and represents a unique metabolite profile (Figure 8B). The OPLS-DA model parameters and
validation of the plot suggest a strong model with the p CV-ANOVA = 0.0094, indicating that the model
was valid (p < 0.5). From the data visualisation below (Figure 8B), strong effects can be predicted on the
level of lipophilic metabolites when ester (T2) and acid (T3) treatments are applied to the THP-1 cells.
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Figure 8. (A) Principle component analysis (PCA-X) vs. (B) Orthogonal Partial Least Squares
Discriminant Analysis (OPLS-DA) score plots of THP-1 cells. The figures show a clear separation
between control, pooled and treatment groups based on 314 non-polar metabolites separated on an
ACE C4 column (n = 4). PCA score plot (A) gives the goodness of fit (R2X) = 0.571, and the goodness of
prediction (Q2) = 0.403. OPLS-DA score plot (B) gives R2X = 0.697, R2Y = 0.982, Q2 = 0.628. (C: Control;
LPS: Lipopolysaccharide; T1(1–4): (11E-OH) eicosenol + LPS; T2(1–4): (11E-ester) eicosenoate + LPS;
T3(1–4): (11E-acid) eicosenoic acid + LPS; p = pooled samples).
Table 3 summarises the list of metabolites separated on the ACE C4 column in cells treated with
eicosenoids in combination with LPS. The metabolites were identified by matching the retention times
to those of a standard mixture of known fatty acids.
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Table 3. Significantly changed non-polar metabolites in THP-1 cells treated with lipopolysaccharide (LPS), alone or in combination with one of three synthetic forms of
honey bee eicosenoids (0.5 µg/mL LPS; 9 µg/mL 11E-OH; 150 µg/mL 11E-ester; 40 µg/mL 11E-acid). Data are compared with those from untreated control cells.
Mass Rt Putative Metabolite
LPS/C 11E-OH + LPS/C 11E-Ester + LPS/C 11E-Acid + LPS/C
Ratio p Value Ratio p Value Ratio p Value Ratio p Value
Fatty Acid and Related Metabolites
306.256 19.23 Icosatrienoic acid * 1.963 <0.001 2.976 0.001 7.296 <0.001 2.941 <0.001
328.240 18.11 Docosahexaenoic acid * 1.637 0.007 2.005 0.003 4.187 <0.001 2.336 <0.001
336.303 22.99 Docosadienoic acid * 1.058 ns 1.021 ns 2.301 <0.001 1.027 ns
282.256 19.94 Oleic acid * 1.126 ns 1.189 0.034 2.938 <0.001 1.391 0.003
216.136 4.28 Undecanedioic acid 1.181 0.041 1.463 0.001 9.890 <0.001 1.487 0.003
214.193 14.92 Tridecanoic acid * 1.138 ns 1.102 ns 1.731 0.018 1.323 0.004
334.287 21.67 Docosatrienoic acid * 1.288 0.050 1.346 0.018 3.345 <0.001 1.523 0.006
398.339 24.40 Axillarenic acid * 1.167 ns 1.118 0.023 1.331 0.039 1.190 0.007
366.350 26.47 Tetracosenoic acid * 1.322 0.001 1.632 <0.001 6.416 <0.001 4.085 0.018
230.152 7.29 Dodecanedioic acid 1.071 ns 1.313 ns 23.842 <0.001 1.352 0.023
258.183 12.16 Tetradecanedioic acid 1.342 ns 1.231 ns 23.897 0.009 1.573 0.030
242.225 17.85 Pentadecanoic acid * 1.021 ns 1.084 ns 1.711 0.017 1.233 0.039
248.178 12.32 Hexadecatetraenoic acid 1.205 ns 1.837 ns 2.553 0.017 2.041 0.044
298.287 23.03 Nonadecanoic acid * 1.133 0.001 1.133 ns 1.310 0.001 1.219 <0.001
332.272 20.18 Docosatetraenoic acid * 1.664 0.004 2.549 <0.001 4.261 <0.001 2.348 <0.001
304.240 18.24 Eicosatetraenoic acid * 1.578 0.006 2.874 <0.001 6.998 <0.001 2.985 <0.001
338.319 24.50 Docosenoic acid * 1.155 0.050 1.871 <0.001 22.311 <0.001 8.335 <0.001
394.381 28.24 Hexacosenoic acid * 1.433 <0.001 1.047 ns 1.903 <0.001 1.685 <0.001
364.334 25.02 Tetracosadienoic acid * 0.888 ns 1.409 ns 3.193 <0.001 2.568 <0.001
202.120 4.64 Decanedioic acid 1.134 ns 1.441 0.008 1.944 0.007 1.204 ns
226.193 15.21 Tetradecenoic acid * 0.820 ns 0.941 ns 1.660 0.009 0.963 ns
186.162 11.81 Undecanoic acid * 1.065 ns 0.898 ns 1.864 0.015 1.238 ns
158.131 8.54 Nonanoic acid * 1.084 ns 0.946 ns 1.714 0.019 1.370 ns
280.240 18.26 Linoleate * 1.169 ns 1.052 ns 1.617 <0.001 1.202 ns
172.110 4.54 9-Oxononanoic acid 1.213 ns 1.231 ns 1.497 ns 1.388 0.031
368.220 11.57 Prostaglandin G2 1.358 ns 1.841 0.026 3.300 0.003 2.432 0.008
356.257 14.60 Prostaglandin F1alpha 1.203 ns 1.446 0.021 1.927 <0.001 1.544 0.001
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Table 3. Cont.
Mass Rt Putative Metabolite
LPS/C 11E-OH + LPS/C 11E-Ester + LPS/C 11E-Acid + LPS/C
Ratio p Value Ratio p Value Ratio p Value Ratio p Value
Glycerophospholipids
638.396 13.80 PA (32:5) 1.549 ns 1.510 ns 2.748 0.021 2.678 ns
847.645 29.88 PC (42:6) 0.963 ns 3.742 <0.001 4.541 <0.001 2.501 0.019
825.530 18.21 PC (40:10) 0.897 0.042 0.753 0.031 0.551 0.002 0.563 <0.001
851.546 18.59 PC (42:11) 0.821 0.016 0.574 <0.001 0.269 <0.001 0.406 <0.001
881.593 21.81 PC (44:10) 1.016 ns 1.743 0.002 2.051 <0.001 1.090 ns
722.545 24.76 PG (33:0) 0.884 ns 0.933 ns 0.857 ns 0.515 0.001
484.280 22.13 Lyso PG (16:0) 1.056 ns 0.876 ns 0.817 0.002 0.942 ns
482.264 7.32 Lyso PG (16:1) 0.833 ns 1.097 ns 0.820 0.050 0.942 ns
572.296 7.29 Lyso PI (16:0) 1.028 ns 1.137 0.027 1.268 0.001 1.200 0.001
598.312 7.95 Lyso PI (18:1) 1.031 ns 1.241 0.007 1.563 <0.001 1.303 0.004
622.312 7.71 Lyso PI (20:3) 1.119 ns 1.302 0.020 1.154 ns 1.255 0.031
620.296 7.04 lyso PI (20:4) 1.152 ns 1.187 0.045 1.891 <0.001 1.770 <0.001
495.260 6.38 lyso PS (16:1) 1.015 ns 0.885 ns 0.730 0.004 0.818 0.036
771.505 24.05 PS (35:3) 0.647 0.001 0.434 <0.001 0.315 <0.001 0.272 <0.001
497.275 7.72 Lyso PS (16:0) 1.033 ns 1.139 ns 0.801 0.011 1.036 ns
517.244 12.63 Lyso PS 18:4 1.689 0.040 1.922 <0.001 2.208 0.020 1.390 ns
691.441 12.63 PS (29:1) 1.380 ns 2.276 0.038 2.380 ns 2.448 ns
Rt: Retention time (min); LPS: Lipopolysaccharides; *: Matches the analytical standard retention time; ns: Non-significant; n/a: Not applicable.
Vaccines 2019, 7, 142 18 of 26
4. Discussion
A recognition of the crucial role of the regulation of the adaptive response and induction of the
innate immune response has led to a reassessment of the role of adjuvants in vaccinology. Recent
studies oninnate immunity activation of macrophages and DCs are now providing better glimpses into
the mechanisms underlying adjuvant actions. These new insights now support the development of
novel adjuvants and combinations of adjuvants to enhance the recognition of antigens by the immune
system and to induce more potent cellular immune responses that exploit the advantages of each
individual component. To the best of our knowledge, no study has yet investigated the eicosenoid
effect on immune macrophage cells. Therefore, the aim of this study was to assess the ability of three
eicosenoid derivatives to induce specific immunological functions of THP-1 macrophage cells by
examining cytokine production and eicosenoid-induced alterations in the cell metabolome.
THP-1 cell viability in the presence of (Z)-11-eicosenol, methyl cis-11-eicosenoate and
cis-11-eicosenoic acid revealed different IC50 values, indicating an effect of functional group substitution
on cellular respiration. The lowest IC50 value was obtained with (Z)-11-eicosenol, which contains a
hydroxyl group (Figure 1), in comparison with the ester and carboxylic acid forms. Several studies
have assessed the effect of functional groups on different cell lines. For example, Sakagami et al.
reported the structure–activity relationships of 11 piperic acid ester derivatives based on their cytotoxic
effects against oral squamous cell carcinoma cell lines and found that addition of two hydroxyl groups
had the highest cytotoxic effect [27]. Similarly, polyhydroxylated analogues of resveratrol, a natural
polyphenol compound, showed higher cytotoxic effects [28].
Previously, (Z)-9-eicosenol was purified from honey bee venom and its stimulatory effect on
TNF-α and IL-1β secretion was reported in the U937 cell line stimulated with LPS, where a surprising
observation was significant inhibition of the level of IL-6 in response to this compound [18]. For this
reason, in the present study, other eicosenoid derivatives were examined for their effects on the cellular
immune response and in particular for their effects on the production of pro and anti- inflammatory
cytokines by THP-1 macrophage cells. All three derivatives showed similar bioactivity with respect
to the induction of cytokine levels, as described previously [18]. A small effect was observed for the
secretion of TNF-α, whereas IL-1β production was enhanced significantly by the 11E-ester and 11E-acid
forms, when combined with LPS. By contrast, the level of IL-6 decreased, suggesting the presence of a
more subtle mechanism of action for eicosenoids. In addition, release of the anti-inflammatory IL-10
cytokine was largely inhibited, supporting their immune stimulatory effect.
The complexity of the IL-6 cytokine responses has been reported extensively [29]. This cytokine
has dual properties pro- and anti-inflammatory, which are referred to as its classic and trans-signaling
pathways [29]. IL-6 promotes a protective effect in some inflammatory diseases, such as inflammatory
bone destruction and dextran sodium sulphate-induced colitis [30,31]. Several studies have also
demonstrated an association between IL-6 and IL-10 and a requirement for IL-6 in IL-10 production by
T cells to suppress inflammation [32,33]. Interestingly, in the current case, both IL-6 and IL-10 were
decreased in the same manner (i.e., the 11E-ester form strongly decreased their secretion, with weaker
decreases by the 11E-acid and still weaker effects by the 11E-OH form). Therefore, the important
consequences on the therapeutic blockade of IL-6 as a treatment of chronic inflammatory diseases
should be carefully considered.
The ability of synthetic eicosenoid derivatives to induce immune responses and to alter cytokine
production was investigated further by a comprehensive untargeted metabolomics assessment of
PMA-stimulated THP-1 cells. Induction of the characteristic morphology of activated macrophages
as a result of Toll-like receptor (TLR4) activation by LPS has been previously described [34]. Several
biomarkers, including nitric oxide (NO), are used to monitor the inflammatory status of these cells.
Inducible nitric oxide synthase (iNOS) is the main enzyme responsible for the release of large
amounts of NO through the conversion of L-arginine to NO and citrulline [35]. Arginine metabolism
is also involved in the regulation of inflammation through its breakdown into ornithine and urea
by arginase [36]. Upregulation of arginine and proline metabolism was significantly identified by
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metabolomic analysis in response to treatment with the ester and acid forms, as indicated by the
alterations in the levels of NO-related metabolites, including L-arginine, L-citrulline, N-(L-arginino)
succinate, L-proline and L-ornithine (Table 2). L-proline and L-ornithine work as precursors for the
formation of pro-proliferative polyamines and production of extracellular matrix, as a repair phase
response [36]. The enhancement of cytokine production by the 11E-acid form is evident mainly by
the alteration of several pathways, including arginine and proline metabolism, where a significantly
higher number of metabolites was altered by this treatment (Figure S13).
Several studies have shown that metabolic reprogramming of the cell regulates macrophage
activation. In the present study, the findings for LPS activation of THP-1 macrophages regarding
specific pathway and biomarker metabolites are consistent with those of previous reports [17,37].
In general, pro-inflammatory stimuli cause the macrophages to undergo a metabolic switch from
oxidative phosphorylation (OXPHOS) to glycolysis [38]. The lactate flux from pyruvate increases in
response to a reduction in acetyl-coenzyme A (acetyl-CoA) levels [38,39] leading to dysfunctional
activity of the TCA cycle, which is, in turn, compensated for by an increase in glycolytic flux to ensure
a rapid regeneration of adenosine triphosphate (ATP) [40].
LPS enhanced activities clearly shown by the combination treatments with eicosenoid derivatives
in this study. The levels of ATP were reduced in the treatments with LPS alone and in combination
with eicosenoids, when compared with untreated control cells suggesting an increased requirement
in the treated cells, leading to upregulation of most of the glycolysis metabolites, including fructose
1,6-bisphosphate and fructose 6-phosphate. In order to maintain a high cellular redox state, PPP
activity was increased. LPS is reported to suppress the expression of carbohydrate kinase-like protein
(CARKL), which is associated with a greater flux into glycolysis and away from the non-oxidative
PPP [40]. This would lead to a significant decrease of sedoheptulose-7-phosphate (S7P) [41]; however,
the opposite was observed for all three treatments with LPS when compared with the untreated control.
The reason for this is not clear.
The TCA cycle intermediates, such as succinate and citrate, are critical in M1 macrophage
activation and are positively associated with inflammation [38]. High levels of succinate were observed
in the present study in response to LPS alone and with the 11E-acid and LPS combination. This
increase has been attributed to glutamine metabolism following dysfunction of the TCA cycle, which
normally would provide the source for succinate generation [42]. Succinate drives inflammation
through the inhibition of prolyl hydroxylase (PHD) and further stabilisation of hypoxia-inducible
factor-1α (HIF-1α) [38]. LPS triggers T-cell activation and the adaptive immune system through an
increased expression of the citrate transport carrier, which could lead to cytosolic citrate accumulation.
This citrate is then converted to acetyl-CoA and oxaloacetate for fatty acid synthesis and generation
of NO and reactive oxygen species (ROS), respectively [43]. Interestingly, in the current study, the
citrate levels were approximately 20% higher in the 11E-ester and 11E-acid combinations with LPS
when compared with LPS alone. Clearly, citrate and succinate are important signaling molecules in
innate and adaptive immunity [44]. Furthermore, the levels of itaconate, a metabolite synthesised via
decarboxylation of cis-aconitate, were elevated in the LPS-activated macrophages. This metabolite
has been suggested to work as an anti-microbial, to limit inflammation and to have a crucial role in
macrophage-based immune responses [45–47]. Interestingly, cis-aconitate was significantly elevated
following the ester and acid form treatments, while itaconate was not detected (Table 2).
An imbalance between cellular oxidants and antioxidants can potentially lead to oxidative
stress and cell damage. Therefore, antioxidant defence is required for cellular adaptation to stress
conditions [48]. Glutathione (GSH), an important protective antioxidant tripeptide, has been implicated
in inflammatory responses and immune modulation [49]. GSH is oxidised to glutathione disulphide
(GSSG) when it reacts with peroxide (H2O2) in the presence of glutathione peroxidase, an enzyme that
facilitates the inactivation of peroxide [50]. GSSG can be reduced again using nicotinamide adenine
dinucleotide phosphate (NADPH). Therefore, regulation of both the NADPH/NADP+ and GSH/GSSG
ratios is tightly coupled to the control of oxidative stress (Figure 9) [51,52]. A decrease in the level of
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GSH and an increase in its product GSSG was observed in this study; this response has been reported
as a hallmark of oxidative stress [53,54]. A large depletion in the level of NADPH and an increase in
NADP+ were observed in the current study after the combination treatment of eicosenoids and LPS
(Table 2). NADPH generates ROS through NADPH oxidase, and it also serves as a substrate for the
conversion of arginine to citrulline and NO [55,56]; arginine and citrulline were also strongly elevated
in response to the treatments with LPS in combination with 11E-ester or 11E-acid (Figure 9).
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Figure 9. Role of nicotinamide adenine dinucleotide phosphate (NADPH) in generating hydrogen
peroxide (H2O2) and nitric oxide (NO) through glutathione metabolism and arginine biosynthesis
in THP-1 macrophages and show (A) Enhanced activity of oxidative stress related metabolites after
treatment with 11E-ester+LPS and 11E-acid+LPS when compared with LPS alone. (B) Overexpression
(dark red) of most of the significant metabolites can be observed in a heat map visualising by
11E-ester+LPS and 11E-acid+LPS treatments. (C) GSH, GSSG and GSH/GSSG responses after
each group treatments. (D) NADPH, NADP+ and NADPH/NADP+ responses after each group
treatments. C: Untreated control; LPS: Lipopolysaccharide; (11E-OH): (Z)-11-eicosenol; (11E-ester):
Eicosenoate; (11E-acid): Eicosenoic acid; (Red rows): Response of 11E-ester+LPS and 11E-acid+LPS
combination treatments.
Enhanced activity of the PPP boosts the production of purine and pyrimidine nucleotides for
further biosynthesis in activated cells [38]. An increase in inosine, guanosine, hypoxanthine, xanthine
and urate levels was detected in the present study. In purine metabolism, xanthine oxidase catalyses
the oxidation of hypoxanthine to xanthine and H2O2 and then to uric acid [23]. Xanthine oxidase
inhibitors, such as allopurinol, can limit the inflammation in a mouse model of arthritis [57]. This
suppression of inflammation is associated with an elevation of several metabolites, including inosine,
guanosine and xanthosine, which are substrates of purine nucleoside phosphorylase (PNP). A loss of
PNP activity or accumulation of one or more enzyme substrates has been linked extensively to immune
deficiency [58]. However, the observation of upregulation in the level of substrates and products of
xanthine oxidase and PNP enzymes in the present study (Figure 10) suggests an ability of eicosenoid
derivatives (particularly 11E-ester and 11E-acid form) to modulate the activity of these enzymes and to
perturb the purine nucleotide pathway in order to boost the immune system through the provision
of ROS.
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Figure 10. Schematic representation of the purine metabolism. This reflects how 11E-ester + LPS and 
11E-acid + LPS synergise the effect of LPS alone focusing on hypoxanthine, xanthine and uric acid, 
which accumulated with H2O2 and superoxide (O2−) during purine degradations. C: Untreated 
control; LPS: Lipopolysaccharide; (11E-OH): (Z)-11-eicosenol; (11E-ester): Eicosenoate; (11E-acid): 
Eicosenoic acid; (Red rows): Response of 11E-ester + LPS and 11E-acid + LPS combination treatments; 
Figure 10. Schematic representation of the purine metabolism. This reflects how 11E-ester + LPS and
11E-acid + LPS synergise the effect of LPS alone focusing on hypoxanthine, xanthine and uric acid,
which accumulated with H2O2 and superoxide (O2−) during purine degradations. C: Untreated control;
LPS: Lipopolysaccharide; (11E-OH): (Z)-11-eicosenol; (11E-ester): Eicosenoate; (11E-acid): Eicosenoic
acid; (Red rows): Response of 11E-ester + LPS and 11E-acid + LPS combination treatments; ATP:
Adenosine triphosphate; AMP: Adenosine monophosphate; **: Significant (p < 0.01); ***: Significant
(p < 0.001).
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Recent research has reflected a significantly increased interest in fatty acid metabolism and its effects
on inflammation and immune cells. In activated macrophages, the importance of mitochondrial fatty
acid metabolism or fatty acid oxidation (FAO) has been considered to reflect the regeneration of ATP and
a compensation for the reduction in ATP levels [59]. Several studies have highlighted the possibility of
attenuating inflammation by promoting macrophage FAO, which also reduces lipid-induced triglyceride
accumulation [60]. Inhibition of FAO in THP-1 cells macrophages exacerbates palmitate-induced
endoplasmic reticulum stress and inflammation responses [61]. In addition, LPS-induced inflammation
results in elevated levels of kidney triglyceride, fatty acid and cholesteryl ester through a decrease in
fatty acid beta oxidation [62]. Intriguingly, the levels of fatty acids were highly elevated in response to
the treatments with LPS in combination with eicosenoids when compared with cells treated with LPS
alone or untreated controls. In the present study, treatment with 11E-ester and 11E-acid in particular
led to increases in a large number of fatty acids, such as arachidonic acid (i.e., eicosatetraenoic acid),
docosenoic acid, tetracosenoic acid, eicosenoic acid and icosatrienoic acid (Table 3), which all are
strongly correlated with inflammation and immune activation. The presence of elevated levels of
several dioic acids (decandioic, dodecandioic and tetradecandoic acids) suggests that the eicosanoic
acid and its ester are functioning as peroxisome proliferator ligands since dioic acids are products of
peroxisome activity [63].
Lipid profiles (lipidomics) and full assessment of their levels, including eicosanoid, are effective
ways to diagnose the severity and progression of several diseases [64,65]. Arachidonic acid (AA), a
precursor of eicosanoids, is considered to represent a potent signal of cellular responses. AA metabolites
are involved in the inflammatory and immune responses [66], and the activation of phospholipase A2
(PLA2) is critical for increasing the AA level and subsequent eicosanoid biosynthesis. TLR4-mediated
priming has been observed to activate cytosolic calcium-dependent PLA2 (cPLA2) and to enhance
cyclooxygenase (COX2) production via Nuclear factor-kappa B (NF-κB), which results in release of AA
and pro-inflammatory eicosanoids [65]. In the present study, the level of AA was strongly elevated
by all the combination treatments when compared to LPS alone; however, this elevation was more
pronounced with 11E-ester form, which resulted in a seven-fold increase in the AA level.
Comprehensive assessment of lipid-correlated inflammatory signaling could provide a better
understanding of cytokine integration with fatty acid metabolism and particular the production of
eicosanoids. In general, the suppression of β-oxidation of fatty acids could result in the apparent
boost in fatty acid synthesis and the reductions in ATP levels and citrate accumulation observed in the
present study. A more targeted investigation is therefore required to confirm the proposed use of these
eicosenoid derivatives as immune system stimulators and as vaccine adjuvants.
5. Conclusions
A deeper understanding of the modes of action that regulate the immune stimulatory properties
of new or existing adjuvants is prerequisite for the rational design of more sophisticated vaccines. The
present study identifies the main effects of synthetic compounds related to 11-eicosanol, which is found
in bee venom, in modulating macrophage behaviour. In agreement with previous findings [17,37],
a stimulatory effect of LPS was confirmed in PMA-differentiated THP-1 cells. Furthermore, the possible
use of (Z)-11-eicosenol, methyl cis-11-eicosenoate and cis-11-eicosenoic acid to alter macrophage
cytokine production was studied. Although these eicosenoid compounds enhanced the production of
IL-1β and suppressed the production of IL-10, which mirrored their immune stimulatory effects, IL-6
release was inhibited, suggesting the presence of a more subtle mechanism of immune modulation.
Further metabolic investigations were therefore performed to obtain a better understanding of changes
in the macrophage metabolome. Alterations in metabolite levels in response to LPS treatment in
the presence or absence of eicosenoids reflected the strength of the actions of each component and
confirmed the potential of these compounds, particularly the ester and acid forms, to synergise LPS
action. Overall, the findings supported their actions as pro- rather than anti-inflammatory agents.
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Significant alterations were observed in the metabolite levels associated with different pathways,
including redox cell signaling pathways, which have been extensively associated with transcriptional
immune factors and immune functions [50,67]. These alterations occurred concomitantly with
upregulation of the levels of several metabolites within the arginine and proline pathways, glycolysis,
the TCA cycle and purine metabolism. Moreover, marked increases occurred in the levels of several fatty
acids and inflammatory biomarker metabolites, including arachidonic acid. Cellular activation and
enhanced immune response were confirmed by the effects of (Z)-11-eicosenol, methyl cis-11-eicosenoate
and cis-11-eicosenoic acid, the findings suggested their possible use as immune-modulating agents and
vaccine adjuvants. Taken together, these findings provide a better understanding of the mechanism
of immune stimulation, and they support the potential use of new adjuvants in shaping a desired
immune response. Comparison with existing adjuvants would need to be carried out in order to
confirm any advantages of the eicosenoids.
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